![norry cad norry cad](https://mediavault.point2.com/p2h/listing/2019/38aa/0239/a38ff64f0ae4cf7d6daa/nwm_large.jpg)
On average, 43% of Tcells in the MP expressed the TCR (range 23 to 63%). MP expanded by an average of 15.3fold during manufacturing (range 5.9 to 25.6-fold). All other pts have had best overall response of stable disease. One pt with head and neck cancer also had a PR. To date, 1 pt with EGJ cancer had a partial response (PR per RECIST) and has had progression-free survival >6 months. Results: As of 16 July 2020, 5 pts (1 with MRCLS, 2 with esophagogastric junction cancers, 1 with ovarian cancer, and 1 with head and neck cancer) were treated with ADP-A2M4 CD8 (range ~1 to 5.7 billion transduced cells). Prior to infusion, pts receive lymphodepletion with fludarabine 30 mg/m 2/day for 4 days and cyclophosphamide 600 mg/m 2/day for 3 days.
![norry cad norry cad](https://images.fineartamerica.com/images/artworkimages/mediumlarge/3/dont-worry-i-have-a-plan-d20-for-dungeon-rpg-gamer-yvonne-remick.jpg)
Expansion, transduction level, cellular composition and function of the manufactured product (MP) are assessed in vitro. Eligible pts undergo apheresis, Tcells are isolated, transduced with a Lentiviral vector containing the MAGE-A4 c1032 TCR and CD8α coreceptor, and expanded.
#Norry cad trial
Methods: First-in-human trial in HLA-A*02 positive patients (pts) with advanced cancers expressing MAGE-A4 antigen by immunohistochemistry. Louis, MO, United States of America, 4Princess Margaret Cancer Centre, Toronto, Ontario, Canada, 5Adaptimmune, Philadelphia, PA, United States of America, 6Adaptimmune, Abingdon, United Kingdomīackground: The ongoing SURPASS trial (NCT04044859) evaluates safety and efficacy of next-generation ADP-A2M4CD8 SPEAR T-cells co-expressing the CD8α co-receptor with the engineered MAGE-A4 c1032 Tcell receptor (TCR). Butler 4Īffiliations ( I nstitution, City, State, Country ) :ġThe University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 2Duke Cancer Center, Durham, NC, United States of America, 3Washington University School of Medicine, St. Brophy 5, Gareth Betts 6, Natalie Bath 6, Will Spinner 6, Alex Tipping 6, Jessica Tucci 5, Raymond Luke 5, Trupti Trivedi 5, Quan Lin 5, JeanMarc Navenot 5, Paula M. Fracasso 5, Karen Miller 6, Elliot Norry 5, Mark Dudley 5, Marcus O. Hong 1, Jeffrey Clarke 2, Tanner Johanns 3, Partow Kebriaei 1, John V. Title: Initial safety, efficacy, and product attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptorĪuthors: David S. Sébastien Desprez - VP, Communications and Investor Relations
#Norry cad update
The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on August 6, 2020, and our other SEC filings. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. These forward-looking statements involve certain risks and uncertainties. This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
#Norry cad full
The Company will update on the full dose escalation cohort of the SURPASS trial (6 patients in total) at the virtual SITC conference on Novemat 9 AM EST when posters are made available online.Īdaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The full abstract is attached to this release. 15, 2020 (GLOBE NEWSWIRE) - Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor” by the Society for the Immunotherapy of Cancer (“SITC”) Conference. PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct.